Advanced Enzyme Technologies: Business Overview & Financial Analysis

Advanced Enzyme Technologies is a research-driven biotechnology company focused on enzymes, probiotics and speciality biological solutions for human nutrition, animal nutrition, food processing and industrial applications. Its products are designed to replace or improve conventional chemical-based processes across healthcare, food and industrial manufacturing. The company serves more than 700 customers across over 45 countries and operates manufacturing and R&D facilities in India, the US and Germany.

Advanced Enzyme Technologies Product and Operating Platform

The company operates across four major business categories, giving it exposure to both healthcare-oriented applications and industrial bio-processing. Human Nutrition remains the largest business, while Industrial Bio-processing and Specialized Manufacturing delivered the strongest growth in Q1 FY27.

• Human Nutrition: Enzymes, probiotics and nutritional solutions used across healthcare and nutraceutical applications.
• Animal Nutrition: Enzyme and probiotic solutions aimed at improving feed efficiency and animal nutrition.
• Industrial Bio-processing: Enzyme solutions for food and non-food applications.
• Specialized Manufacturing: Contributed around 11% of Q1 FY27 revenue.
• Proprietary portfolio: More than 400 products.
• Technology base: More than 68 enzymes and probiotics.
• Customer base: More than 700 customers globally.
• Geographic reach: More than 45 countries.

The diversified application base reduces dependence on a single end market, although Human Nutrition continues to account for the majority of consolidated revenue.

Advanced Enzyme Technologies Manufacturing and R&D Infrastructure

Advanced Enzyme Technologies combines in-house fermentation capabilities with research centres across three countries. Its R&D platform supports development of new enzymes, probiotics and application-specific solutions.

• Manufacturing units: 9, comprising 8 in India and 1 in the US.
• R&D units: 7, including 5 in India, 1 in the US and 1 in Germany.
• Fermentation capacity: Around 500 cubic metres.
• Fermentation experience: More than 30 years.
• Employees: More than 750.
• Patents: 15, including filed applications, as of FY26-end.
• EFSA food-enzyme dossiers: 17 filed.
• GRAS dossiers: 10 evaluated by the US FDA.
• Novel Food dossier: 1 filed with EFSA and under evaluation.

The combination of fermentation, application development and regulatory filings creates higher technical entry barriers than a simple formulation or distribution-led business model.

Advanced Enzyme Technologies Human Nutrition Business (Q1 FY27)

Human Nutrition remained the largest revenue contributor during Q1 FY27, but revenue declined compared with both the previous year and the preceding quarter.

• Q1 FY27 revenue: Rs 113.9 crore.
• Q1 FY26 revenue: Rs 122.1 crore.
• YoY change: Down 7%.
• Sequential change: Down 11%.
• Revenue contribution: Around 60% of consolidated revenue.
• Focus areas: Pharma/API enzymes, probiotics, bio-catalysis and broader nutrition applications.

The performance of Human Nutrition remains important for overall growth because its revenue contribution is substantially larger than that of the other operating categories.

Advanced Enzyme Technologies Animal Nutrition Business (Q1 FY27)

Animal Nutrition provides enzymes and probiotics used to support animal-feed performance and nutrition. Q1 FY27 revenue remained broadly stable but was slightly lower year-on-year.

• Q1 FY27 revenue: Rs 25.2 crore.
• Q1 FY26 revenue: Rs 26.0 crore.
• YoY change: Down 3%.
• Sequential change: Up 1%.
• Revenue contribution: Around 13% of consolidated revenue.
• Growth focus: New product trials, registrations and wider international distribution.

Management's strategy is to increase product registrations and expand commercial reach across the US, MENA and Asian markets rather than relying only on the existing domestic portfolio.

Advanced Enzyme Technologies Industrial Bio-processing Business (Q1 FY27)

Industrial Bio-processing was the strongest-growing major operating category in Q1 FY27. Growth was driven by food applications, while non-food applications declined.

• Q1 FY27 revenue: Rs 30.6 crore.
• Q1 FY26 revenue: Rs 23.6 crore.
• YoY growth: 30%.
• Revenue contribution: Around 16%.
• Food business revenue: Rs 26.3 crore, up 51% YoY.
• Food contribution: Around 14% of consolidated revenue.
• Non-food revenue: Rs 4.3 crore, down 30% YoY.
• Sequential segment change: Down 5%.

Food-processing enzymes are therefore becoming an increasingly important part of Industrial Bio-processing, while the non-food business remained comparatively weak during the quarter.

Advanced Enzyme Technologies Specialized Manufacturing (Q1 FY27)

Specialized Manufacturing recorded the fastest growth among the four operating categories in Q1 FY27. Although it remains smaller than Human Nutrition, its contribution has been increasing.

• Q1 FY27 revenue: Rs 20.0 crore.
• Q1 FY26 revenue: Rs 14.2 crore.
• YoY growth: 41%.
• Q4 FY26 revenue: Rs 18.0 crore.
• Sequential growth: 11%.
• Revenue contribution: Around 11% of consolidated revenue.

The segment's faster growth is gradually improving diversification across the consolidated revenue mix.

Advanced Enzyme Technologies Geographic Revenue Mix (Q1 FY27)

International markets contributed just over half of consolidated revenue during Q1 FY27. Europe and Asia recorded strong growth, while India and the Americas declined slightly.

• India: Rs 93.7 crore, 49% of revenue, down 4% YoY.
• Americas: Rs 54.6 crore, 29% of revenue, down 3%.
• Europe: Rs 13.2 crore, 7% of revenue, up 44%.
• Asia excluding India: Rs 24.2 crore, 13% of revenue, up 37%.
• Rest of the World: Rs 4.0 crore, 2% of revenue, down 15%.
• International contribution: Around 51% of Q1 FY27 revenue.

The strong growth in Europe and other Asian markets partly offset weaker performance in India and the Americas, highlighting the benefit of the company's diversified geographic presence.

Advanced Enzyme Technologies Q1 FY27 Financial Performance

Consolidated revenue increased marginally during Q1 FY27, but EBITDA and PAT declined because profitability did not keep pace with sales. The quarter was also weaker sequentially compared with Q4 FY26.

• Revenue: Rs 189.8 crore, up 2% YoY.
• EBITDA: Rs 51.0 crore, down 10% YoY.
• EBITDA margin: 27% versus around 30% in Q1 FY26.
• PAT: Rs 38.6 crore, down 5% YoY.
• PAT margin: 20%.
• Sequential revenue change: Down 7%.
• Sequential EBITDA change: Down 19%.
• Sequential PAT change: Down 15%.

The latest quarter therefore showed a mixed operating performance, with growth in Industrial Bio-processing and Specialized Manufacturing offset by weakness in the larger Human Nutrition business and lower consolidated margins.

Advanced Enzyme Technologies FY26 Financial and Balance-Sheet Base

FY26 recorded healthy growth in consolidated revenue, EBITDA and PAT, providing a stronger annual base before the softer profitability seen in Q1 FY27.

• FY26 consolidated revenue: Rs 745.8 crore versus Rs 636.9 crore in FY25.
• FY26 EBITDA: Rs 229.1 crore versus Rs 194.4 crore.
• EBITDA margin: Around 31%.
• FY26 PAT: Rs 173.6 crore versus Rs 134.0 crore.
• PAT margin: Around 23%.
• Net worth: Rs 1,632 crore at FY26-end.
• Net working-capital cycle: 138 days.
• Net debt-to-equity: 0.01x.
• ROE: 11.37%.
• ROCE: 12.21%.

The low net leverage provides flexibility for R&D, product development and acquisitions, although the working-capital cycle remains relatively long.

Advanced Enzyme Technologies Management Commentary and Outlook (Q1 FY27)

Management's disclosed growth priorities centre on increasing geographic penetration, developing higher-value applications and continuing investment in enzymes, probiotics and bio-catalysis. The company has not provided a specific FY27 revenue or profit forecast in the supplied presentation.

• Animal Nutrition: Continue trials and introduce additional products in domestic and international markets.
• International expansion: Add sales and marketing resources across the US, MENA and Asia.
• Distribution: Increase the number of overseas distributors.
• Bio-catalysis: Develop enzyme-based solutions for API manufacturers to reduce energy, processing time and chemical usage.
• API trials: A couple of bio-catalysis products were at advanced plant-trial stages.
• Probiotics: Develop additional products for immunity, gut health and nutraceutical applications.
• Baking: Expand enzyme solutions across Europe, the Americas and other international markets.
• R&D and M&A: Continue investment in new enzymes and probiotics while evaluating technologies, capabilities and customer relationships through inorganic opportunities.

The main indicators to track are recovery in Human Nutrition, growth in food enzymes, Specialized Manufacturing momentum, international expansion, margin recovery, bio-catalysis commercialisation and working-capital efficiency.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Sources & References

This company fact sheet has been prepared using Advanced Enzyme Technologies' latest annual, quarterly and management disclosures together with financial information available on Finology Ticker.

• Advanced Enzyme Technologies Annual Report FY 2025-26
• Advanced Enzyme Technologies Q1 FY27 Earnings Presentation
• Advanced Enzyme Technologies Q1 FY27 Earnings Conference Call Transcript
• Finology Ticker - Advanced Enzyme Technologies Company Page

Disclaimer
The information presented above on Advanced Enzyme Technologies has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings, and the financial data available on Finology Ticker. Certain figures, classifications, or comparisons may vary due to differences in accounting policies, reporting methodologies, or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios, and disclosures available on the Finology Ticker Advanced Enzyme Technologies page before making any investment decision. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.